The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis

Published:2021-05-04 Issue:3 Volume:43 Page:386-394
ISSN:0892-3973
Container-title:Immunopharmacology and Immunotoxicology
language:en
Short-container-title:Immunopharmacology and Immunotoxicology

Author:

Xu Yao¹²,Hezam Kamal²³⁴,Ali Manasik Gumah²,Wang Yang⁵,Zhang Juan²

Affiliation:

1. Sanhome-CPU Joint Laboratory, China Pharmaceutical University, Nanjing, PR China

2. Antibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing, PR China

3. Nankai University School of Medicine, Tianjin, PR China

4. Faculty of Applied Science, Taiz University, Taiz, Yemen

5. Institute of Immunotherapy, Fujian Medical University, Minhou County, Fuzhou, China

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/08923973.2021.1924195

Reference38 articles.

1. Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength

2. CTLA-4: new insights into its biological function and use in tumor immunotherapy

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

5. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective activation of IFNγ–ipilimumab enhances the therapeutic effect and safety of ipilimumab;International Journal of Biological Macromolecules;2024-04

2. Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study;Cancer;2024-02-26

3. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer;Frontiers in Medicine;2023-02-09

4. Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review;Cancers;2023-01-22

5. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity;Viral Vectors in Cancer Immunotherapy;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3